The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis

OBJECTIVE: We evaluated the incidence of and the main risk factors associated with cutaneous adverse events in patients with chronic inflammatory arthritis following anti-TNF-α therapy. METHODS: A total of 257 patients with active arthritis who were taking TNF-α blockers, including 158 patients wi...

Full description

Bibliographic Details
Main Authors:	Natalia P. Machado, Edgard Torres dos Reis Neto, Maria Roberta M.P. Soares, Daniele S. Freitas, Adriana Porro, Rozana M. Ciconelli, Marcelo M. Pinheiro
Format:	Article
Language:	English
Published:	Faculdade de Medicina / USP 2013-09-01
Series:	Clinics
Subjects:	TNF-alpha Blockers Skin Adverse Events Rheumatoid Arthritis Ankylosing Spondylitis
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322013000901189&lng=en&tlng=en

Similar Items

Coexistence of Ankylosing Spondylitis and Multiple Sclerosis: Trigger with TNF-alpha Antagonist Therapy or Coincidental?
by: Bahar Say, et al.
Published: (2019-09-01)

A Three Year Retrospective Analysis Of Anti-Tnf Treatment Outcomes In Rheumatoid Arthritis And Ankylosing Spondylitis Patients
by: Seyfettin Üstünsoy, et al.
Published: (2020-09-01)

Classical and paradoxical effects of TNF-α on bone homeostasis
by: Bilal eOsta, et al.
Published: (2014-02-01)

An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus
by: Ursula Schulte-Wrede, et al.
Published: (2018-08-01)

BRAINSTEM AUDITORY EVOKED POTENTIALS FINDINGS IN ANKYLOSING SPONDYLITIS
by: Iulia Georgiana Stamate, et al.
Published: (2015-09-01)

Periodontal Conditions during Arthritis Therapy with TNF-α Blockers
by: Rudolf Schiefelbein, et al.
Published: (2018-10-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs
by: F.M. Perrotta, et al.
Published: (2014-11-01)

Anti-Tumor Necrosis Factor Alpha Treatment and Tuberculin Skin Test
by: Emine Duygu Ersozlu Bozkirli, et al.
Published: (2015-09-01)

Hanseníase virchowiana associada ao uso de inibidor do fator de necrose tumoral α: relato de caso
by: Daniele S Freitas, et al.

IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
by: Milena Iwaszko, et al.
Published: (2021-06-01)

Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis
by: Chitul A., et al.
Published: (2017-03-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
by: Tacjana Anna Barczyńska, et al.
Published: (2015-12-01)

Case 1‑2012: ANCA Associated Glomerulonephritis in Combination with IgG4 Positive Mediastinal Mass in a Patient with Ankylosing Spondylitis Treated with TNF Alpha Inhibitors
by: Marian Tošovský, et al.
Published: (2012-01-01)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
by: Nadia Emi Aikawa, et al.
Published: (2011-01-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
by: Agata Sebastian, et al.
Published: (2017-08-01)

Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis
by: Ki-Nam Gu, et al.
Published: (2019-08-01)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
by: Katarzyna Bogunia-Kubik, et al.
Published: (2021-07-01)

Assessment of Intra- and Inter-individual Variability of Outcome Measures in Ankylosing Spondylitis and the Efficacy and Adverse Effects of Anti-TNF Therapy
by: Maxwell, Lara J
Published: (2011)

Assessment of Intra- and Inter-individual Variability of Outcome Measures in Ankylosing Spondylitis and the Efficacy and Adverse Effects of Anti-TNF Therapy
by: Maxwell, Lara J
Published: (2011)

Assessment of Intra- and Inter-individual Variability of Outcome Measures in Ankylosing Spondylitis and the Efficacy and Adverse Effects of Anti-TNF Therapy
by: Maxwell, Lara J
Published: (2011)

Frequency of the use of biological treatment of patients with rheumatoid arthritis and ankylosing spondylitis in Lower Silesia
by: Wojciech Tański, et al.
Published: (2016-09-01)

TEMPOROMANDIBULAR JOINT INVOLVEMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: A CROSS-SECTIONAL STUDY
by: Cristina Iordache, et al.
Published: (2018-01-01)

Hanseníase virchowiana associada ao uso de inibidor do fator de necrose tumoral α: relato de caso Lepromatous leprosy associated with the use of anti-TNF α therapy: case report
by: Daniele S Freitas, et al.
Published: (2010-06-01)

IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis
by: Jing Liu, et al.
Published: (2019-06-01)

BASELINE INFLAMMATORY MARKERS AND DISEASE ACTIVITY INDICES PREDICT TAPERING OF BIOLOGIC AGENTS IN ANKYLOSING SPONDYLITIS
by: Marius Trandafir, et al.
Published: (2018-03-01)

Mass spectrometry-based analysis of cerebrospinal fluid from arthritis patients—immune-related candidate proteins affected by TNF blocking treatment
by: Johanna Estelius, et al.
Published: (2019-02-01)

Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers
by: Laine J, et al.
Published: (2016-04-01)

Changes of serum TNF-alpha, IL-2 and IL-13 in patients with rheumatoid arthritis
by: Yan Meng, et al.
Published: (2018-02-01)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Philip Brenner, et al.
Published: (2020-02-01)

Frequency of inflammatory back pain and sacroiliitis in Egyptian patients with rheumatoid arthritis
by: N.M.M. Osman, et al.
Published: (2019-09-01)

Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers
by: Tim van der Houwen, et al.
Published: (2020-04-01)

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis
by: Seulkee Lee, et al.
Published: (2021-10-01)

Distinctive Expression of Bone Metabolism-related Genes between PBMCs from Condylar Hyperplasia, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
by: Reza Amirzargar, et al.
Published: (2020-10-01)

Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS
by: Désirée van der Heijde, et al.
Published: (2019-11-01)

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
by: Heslinga SC, et al.
Published: (2018-11-01)

EFFICACY DIFFERENCES BETWEEN CLASSICAL AND BIOLOGICAL TREATMENT IN ANKYLOSING SPONDYLITIS
by: Claudiu Popescu, et al.
Published: (2016-09-01)

GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis
by: Hui Shi, et al.
Published: (2020-07-01)

Cannot write session to /tmp/vufind_sessions/sess_5qo66l9psmn3hcb360n5n4qm6p